A concerted, alternating sites mechanism of ubiquinol oxidation by the dimeric cytochrome bc(1) complex.
A refinement of the protonmotive Q cycle mechanism is proposed in which oxidation of ubiquinol is a concerted reaction and occurs by an alternating, half-of-the-sites mechanism. A concerted mechanism of ubiquinol oxidation is inferred from the finding that there is reciprocal control between the high potential and low potential redox components involved in ubiquinol oxidation. The potential of the Rieske iron-sulfur protein controls the rate of reduction of the b cytochromes, and the potential of the b cytochromes controls the rate of reduction of the Rieske protein and cytochrome c(1). A concerted mechanism of ubiquinol oxidation reconciles the findings that the ubiquinol-cytochrome c reductase kinetics of the bc(1) complex include both a pH dependence and a dependence on Rieske iron-sulfur protein midpoint potential.An alternating, half-of-the-sites mechanism for ubiquinol oxidation is inferred from the finding that some inhibitory analogs of ubiquinol that block ubiquinol oxidation by binding to the ubiquinol oxidation site in the bc(1) complex inhibit the yeast enzyme with a stoichiometry of 0.5 per bc(1) complex. One molecule of inhibitor is sufficient to fully inhibit the dimeric enzyme, and the binding is anti-cooperative, in that a second molecule of inhibitor binds with much lower affinity to a dimer in which an inhibitor molecule is already bound. An alternating, half-of-the-sites mechanism implies that, at least under some conditions, only half of the sites in the dimeric enzyme are reactive at any one time. This provides a raison d'être for the dimeric structure of the enzyme, in that bc(1) activity may be regulated and capable of switching between a half-of-the-sites active and a fully active enzyme.
Trumpower
Bernard L
BL
Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755-3844, USA. Trumpower@Dartmouth.edu
D000968:Antimycin A / Q000031:analogs & derivatives* / Q000737:chemistry; D001665:Binding Sites; D003573:Cytochrome b Group / Q000737:chemistry; D019281:Dimerization; D004579:Electron Transport; D014450:Electron Transport Complex III / Q000737:chemistry*; D006863:Hydrogen-Ion Concentration; D007506:Iron-Sulfur Proteins / Q000737:chemistry; D007700:Kinetics; D008958:Models, Molecular; D009245:NADH Dehydrogenase / Q000737:chemistry; D018892:Proton-Motive Force; D013816:Thermodynamics; D014451:Ubiquinone / Q000031:analogs & derivatives / Q000737:chemistry*; D024482:Vitamin K 2 / Q000737:chemistry
D003573:Cytochrome b Group; D007506:Iron-Sulfur Proteins; C037989:Rieske iron-sulfur protein; D024482:Vitamin K 2; C032456:antimycin; D014451:Ubiquinone; D000968:Antimycin A; D009245:NADH Dehydrogenase; D014450:Electron Transport Complex III; C003741:ubiquinol